CRL vs PTGX · rev $4.02B vs rev $269.8M
Charles River Laboratories (CRL) versus Protagonist Therapeutics Inc (PTGX) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Protagonist Therapeutics Inc (PTGX) is a biotechnology company listed on NASDAQ.
Latest reported CRL revenue for 2025-12-27 was $4.02B. Net income was -$144.3M. CRL currently screens at market cap $7.78B.
Latest reported PTGX revenue for 2026-06-30 was $269.8M. Net income was $166.6M. PTGX currently screens at market cap $7.25B.
CRL currently screens at market cap $7.78B. PTGX currently screens at market cap $7.25B.
Not investment advice. Open the CRL and PTGX stock pages for the full models.
Not investment advice.